ArticleJournal of advanced research2026
Antiviral activity and mechanism of purine morpholine nucleoside analogues incorporating a sulfonamide fragment.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPepper mild mottle virus (PMMoV) poses an enormous threat to pepper production because of its high infectivity and soil persistence. Commercially available antiviral agents, ningnanmycin and ribavirin, have been restricted from widespread use due to their photosensitivity, water viscosity, and unsatisfactory efficacy.
objectivesIn order to synthesize compounds with superior antiviral activities against PMMoV and clarify their antiviral mechanisms.
methodsA series of purine morpholine nucleoside analogues incorporating a sulfonamide moiety were successfully synthesized from D-glucosamine hydrochloride through a systematic multistage reaction involving condensation, acetylation, hydrolysis, sulfonation, bromination, and substitution. And activity-based protein profiling (ABPP) technology, Western blot, and microscale thermophoresis (MST) were combined to validate the target protein of C1 acting on PMMoV. Subsequently, molecular docking, MD simulations, Western blot, and RT-qPCR were employed to identify the key amino acid sites for C1 action. Next, co-immunoprecipitation mass spectrometry (Co-IP MS), RNA sequencing (RNA-seq), luciferase complementation assay (LCA), bimolecular fluorescence complementation (BiFC), and fluorescence recovery after photobleaching (FRAP) were applied to investigate the underlying mechanisms of infection diversity between GFP-PMMoV CP and GFP-PMMoV CP
resultsThirty-eight purine morpholine nucleoside analogues incorporating a sulfonamide fragment with preferable inhibiting activities against PMMoV were designed and synthesized for the first time. ABPP technology, Western blot, and MST manifested that PMMoV CP was the target protein of C1. Molecular docking, MD simulations, RT-qPCR, and Western blot revealed that the tyrosine at position 13 (Tyr13) of PMMoV CP might be the key amino site for C1 action. Co-IP MS, RNA-seq, LCA, BiFC, and FRAP indicated that the discrepancy in the liquid-liquid phase separation (LLPS) between PMMoV CP and PMMoV CP
conclusionOur research revealed that purine morpholine nucleoside analogues containing a sulfonamide fragment possessed preferable inhibitory activities against PMMoV. Correlated mechanism studies indicated that C1 could inhibit the formation of LLPS by specifically targeting Tyr13 of PMMoV CP, thus achieving the purpose of antiviral effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.